{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:15:39Z","timestamp":1753892139467,"version":"3.41.2"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T00:00:00Z","timestamp":1642636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003483","name":"Hebrew University of Jerusalem","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Almost all Duchenne muscular dystrophy (DMD) patients that reach their 30s present cardiomyopathy. As a result, this population remains under-treated. There is no sufficient proof of the efficacy of anti-remodeling cardiac therapy for DMD cardiomyopathy (DMDCM). We aim to assess the efficacy of anti-remodeling cardiac therapy for DMDCM by using meta-analysis.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> PubMed (MEDLINE), Embase, and Cochrane library were searched through January 2021. Randomized control trials, case-control studies, and observational studies that reported assessments of cardiovascular outcomes and death of participants using angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, mineralocorticoid-receptor antagonists and Ivabradine, were included. The primary outcome was total mortality. Secondary outcomes included changes in left ventricular ejection fraction (LVEF), serum natriuretic peptide levels (BNP), and heart rate (HR). Data were extracted for eligibility by two independent reviewers. Random-effects meta-analysis was used to pool results.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Twelve studies with 439 patients were included in our meta-analysis. Treated patients have lower HR, mean difference of \u221217 beats per minute (CI [\u221225]\u2013[\u22129], <jats:italic>p<\/jats:italic> &amp;lt; 0.01). The LVEF was improved in treated patients, with a mean difference of LVEF of 3.77% (CI 0.44\u20137.12, <jats:italic>p<\/jats:italic> &amp;lt; 0.03). Although mortality rates did not reach statistical significance there was a trend for total mortality reduction (hazard ratio 0.36, CI (0.1\u20131.25), <jats:italic>p<\/jats:italic> = 0.107) and for BNP reduction (SSMD: 0.141, CI ([\u22120.19]\u2013[0.47]), <jats:italic>p<\/jats:italic> = 0.3).<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Pharmacologic treatment for DMDCM patients is associated with decreased HR and improved LVEF. Therefore, DMDCM patients may benefit from implementing guideline therapy for HF.<\/jats:p>","DOI":"10.3389\/fphar.2021.769896","type":"journal-article","created":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T07:44:59Z","timestamp":1642664699000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Anti-Remodeling Cardiac Therapy in Patients With Duchenne Muscular Dystrophy, Meta-Analysis Study"],"prefix":"10.3389","volume":"12","author":[{"given":"Bruria Hirsh","family":"Raccah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bar","family":"Biton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Offer","family":"Amir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Israel","family":"Gotsman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dean","family":"Nahman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilan","family":"Matok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/mus.20586","article-title":"Entries in the Leiden Duchenne Muscular Dystrophy Mutation Database: An Overview of Mutation Types and Paradoxical Cases that Confirm the reading-frame Rule","volume":"34","author":"Aartsma-Rus","year":"2006","journal-title":"Muscle Nerve"},{"key":"B2","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ijcard.2019.01.052","article-title":"Heart Rate Reduction Strategy Using Ivabradine in End-Stage Duchenne Cardiomyopathy","volume":"280","author":"Adorisio","year":"2019","journal-title":"Int. J. Cardiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1007\/s00246-018-2046-x","article-title":"Progressive Left Ventricular Dysfunction and Myocardial Fibrosis in Duchenne and Becker Muscular Dystrophy: a Longitudinal Cardiovascular Magnetic Resonance Study","volume":"40","author":"Aikawa","year":"2019","journal-title":"Pediatr. Cardiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.echo.2018.10.017","article-title":"Speckle-Tracking Echocardiography in Children with Duchenne Muscular Dystrophy: A Prospective Multicenter Controlled Cross-Sectional Study","volume":"32","author":"Amedro","year":"2019","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1542\/peds.2005-2448","article-title":"Cardiovascular Health Supervision for Individuals Affected by Duchenne or becker Muscular Dystrophy","volume":"116","year":"2005","journal-title":"Pediatrics"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.jpeds.2013.05.060","article-title":"Oral Corticosteroids and Onset of Cardiomyopathy in Duchenne Muscular Dystrophy","volume":"163","author":"Barber","year":"2013","journal-title":"J. Pediatr."},{"key":"B8","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1474-4422(18)30025-5","article-title":"Diagnosis and Management of Duchenne Muscular Dystrophy, Part 2: Respiratory, Cardiac, Bone Health, and Orthopaedic Management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"CD009068","DOI":"10.1002\/14651858.CD009068.pub3","article-title":"Interventions for Preventing and Treating Cardiac Complications in Duchenne and Becker Muscular Dystrophy and X-Linked Dilated Cardiomyopathy","volume":"10","author":"Bourke","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"B10","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/s0960-8966(02)00213-4","article-title":"107th ENMC International Workshop: the Management of Cardiac Involvement in Muscular Dystrophy and Myotonic Dystrophy. 7th-9th June 2002, Naarden, the Netherlands","volume":"13","author":"Bushby","year":"2003","journal-title":"Neuromuscul. Disord."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1136\/heartjnl-2017-311269","article-title":"A Current Approach to Heart Failure in Duchenne Muscular Dystrophy","volume":"103","author":"D\u2019Amario","year":"2017","journal-title":"Heart"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1096\/fj.01-0030fje","article-title":"Dystrophin-deficient Cardiomyocytes Are Abnormally Vulnerable to Mechanical Stress-Induced Contractile Failure and Injury","volume":"15","author":"Danialou","year":"2001","journal-title":"FASEB J."},{"key":"B13","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13023-019-1066-9","article-title":"Effect and Safety of Treatment with ACE-Inhibitor Enalapril and \u03b2-blocker Metoprolol on the Onset of Left Ventricular Dysfunction in Duchenne Muscular Dystrophy - a Randomized, Double-Blind, Placebo-Controlled Trial","volume":"14","author":"Dittrich","year":"2019","journal-title":"Orphanet J. Rare Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.jacc.2004.09.078","article-title":"Effect of Perindopril on the Onset and Progression of Left Ventricular Dysfunction in Duchenne Muscular Dystrophy","volume":"45","author":"Duboc","year":"2005","journal-title":"J. Am. Coll. Cardiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"18168","DOI":"10.3390\/molecules201018168","article-title":"Duchenne Muscular Dystrophy: from Diagnosis to Therapy","volume":"20","author":"Falzarano","year":"2015","journal-title":"Molecules"},{"key":"B16","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/s0735-1097(03)00581-3","article-title":"Ultrasound Tissue Characterization Detects Preclinical Myocardial Structural Changes in Children Affected by Duchenne Muscular Dystrophy","volume":"42","author":"Giglio","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's Tool for Assessing Risk of Bias in Randomised Trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"B18","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/1532-429X-15-107","article-title":"Prevalence and Distribution of Late Gadolinium Enhancement in a Large Population of Patients with Duchenne Muscular Dystrophy: Effect of Age and Left Ventricular Systolic Function","volume":"15","author":"Hor","year":"2013","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1161\/CIRCULATIONAHA.104.528281","article-title":"Genetic Predictors and Remodeling of Dilated Cardiomyopathy in Muscular Dystrophy","volume":"112","author":"Jefferies","year":"2005","journal-title":"Circulation"},{"key":"B20","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1253\/circj.70.991","article-title":"Beta-Blocker Therapy for Cardiac Dysfunction in Patients with Muscular Dystrophy","volume":"70","author":"Kajimoto","year":"2006","journal-title":"Circ. J."},{"key":"B21","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3390\/children7110249","article-title":"Is it Possible for Children in Duchenne Muscular Dystrophy to Preserve Cardiac Function with Medical Assistance?","volume":"7","author":"Kim","year":"2020","journal-title":"Children (Basel)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jcm9020520","article-title":"Dysregulation of Calcium Handling in Duchenne Muscular Dystrophy-Associated Dilated Cardiomyopathy: Mechanisms and Experimental Therapeutic Strategies","volume":"9","author":"Law","year":"2020","journal-title":"J. Clin. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12933-019-0849-6","article-title":"The Sodium-Glucose Co-transporter 2 Inhibitor Empagliflozin Attenuates Cardiac Fibrosis and Improves Ventricular Hemodynamics in Hypertensive Heart Failure Rats","volume":"18","author":"Lee","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1007\/s00246-005-0909-4","article-title":"Steroid Therapy and Cardiac Function in Duchenne Muscular Dystrophy","volume":"26","author":"Markham","year":"2005","journal-title":"Pediatr. Cardiol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.2169\/internalmedicine.49.3259","article-title":"Carvedilol Can Prevent Cardiac Events in Duchenne Muscular Dystrophy","volume":"49","author":"Matsumura","year":"2010","journal-title":"Intern. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin Inhibition versus Enalapril in Heart Failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1161\/CIRCULATIONAHA.114.015151","article-title":"Contemporary Cardiac Issues in Duchenne Muscular Dystrophy. Working Group of the National Heart, Lung, and Blood Institute in Collaboration with Parent Project Muscular Dystrophy","volume":"131","author":"McNally","year":"2015","journal-title":"Circulation"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 Statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst. Rev."},{"key":"B29","doi-asserted-by":"publisher","first-page":"S100","DOI":"10.1016\/j.cardfail.2005.06.039","article-title":"Limited Utility of BNP in Detection of Left Ventricular Dysfunction in Duchenne Muscular Dystrophy","volume":"11","author":"Mohyuddin","year":"2005","journal-title":"J. Card. Fail."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/S1474-4422(03)00585-4","article-title":"Dystrophin and Mutations: One Gene, Several Proteins, Multiple Phenotypes","volume":"116","author":"Muntoni","year":"2005","journal-title":"Pediatrics"},{"key":"B31","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/0167-5273(90)90082-g","article-title":"The Incidence and Evolution of Cardiomyopathy in Duchenne Muscular Dystrophy","volume":"26","author":"Nigro","year":"1990","journal-title":"Int. J. Cardiol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jjcc.2008.08.013","article-title":"Beneficial Effects of Beta-Blockers and Angiotensin-Converting Enzyme Inhibitors in Duchenne Muscular Dystrophy","volume":"53","author":"Ogata","year":"2009","journal-title":"J. Cardiol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a Web and mobile App for Systematic Reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst. Rev."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/nejmoa2022190","article-title":"Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e0254","DOI":"10.1097\/MD.0000000000010254","article-title":"The Use of a Novel Non-steroidal Mineralocorticoid Receptor Antagonist Finerenone for the Treatment of Chronic Heart Failure: A Systematic Review and Meta-Analysis","volume":"97","author":"Pei","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"B36","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/ejhf.592","article-title":"2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC). Developed with the Special Contribution of the Heart Failure Association (HFA) of the ESC","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur. J. Heart Fail."},{"key":"B37","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S1474-4422(14)70318-7","article-title":"Eplerenone for Early Cardiomyopathy in Duchenne Muscular Dystrophy: a Randomised, Double-Blind, Placebo-Controlled Trial","volume":"14","author":"Raman","year":"2015","journal-title":"Lancet Neurol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s00246-007-9113-z","article-title":"Safety and Efficacy of Carvedilol Therapy for Patients with Dilated Cardiomyopathy Secondary to Muscular Dystrophy","volume":"29","author":"Rhodes","year":"2008","journal-title":"Pediatr. Cardiol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"d549","DOI":"10.1136\/bmj.d549","article-title":"Interpretation of Random Effects Meta-Analyses","volume":"342","author":"Riley","year":"2011","journal-title":"BMJ"},{"key":"B40","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1542\/peds.2014-2044","article-title":"Prevalence of Duchenne and Becker Muscular Dystrophies in the United States","volume":"135","author":"Romitti","year":"2015","journal-title":"Pediatrics"},{"key":"B41","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13023-017-0631-3","article-title":"The burden, Epidemiology, Costs and Treatment for Duchenne Muscular Dystrophy: an Evidence Review","volume":"12","author":"Ryder","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"B42","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/s0002-8703(98)70057-2","article-title":"Sequential Changes in Cardiac Structure and Function in Patients with Duchenne Type Muscular Dystrophy: a Two-Dimensional Echocardiographic Study","volume":"135","author":"Sasaki","year":"1998","journal-title":"Am. Heart J."},{"key":"B43","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.jacc.2012.12.008","article-title":"All-cause Mortality and Cardiovascular Outcomes with Prophylactic Steroid Therapy in Duchenne Muscular Dystrophy","volume":"61","author":"Schram","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1001\/jamacardio.2016.4801","article-title":"Myocardial Fibrosis Progression in Duchenne and Becker Muscular Dystrophy: A Randomized Clinical Trial","volume":"2","author":"Silva","year":"2017","journal-title":"JAMA Cardiol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/S0002-9149(02)03429-X","article-title":"Effects of Deflazacort on Left Ventricular Function in Patients with Duchenne Muscular Dystrophy","volume":"91","author":"Silversides","year":"2003","journal-title":"Am. J. Cardiol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/mus.24163","article-title":"Cooperative International Neuromuscular Research Group Duchenne Natural History Study Demonstrates Insufficient Diagnosis and Treatment of Cardiomyopathy in Duchenne Muscular Dystrophy","volume":"50","author":"Spurney","year":"2014","journal-title":"Muscle Nerve"},{"key":"B47","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of Observational Studies in Epidemiology: a Proposal for Reporting. Meta-Analysis of Observational Studies in Epidemiology (MOOSE) Group","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"B48","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1093\/eurheartj\/14.5.669","article-title":"Discrepancy between Systolic and Diastolic Dysfunction of the Left Ventricle in Patients with Duchenne Muscular Dystrophy","volume":"14","author":"Takenaka","year":"1993","journal-title":"Eur. Heart J."},{"key":"B49","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1056\/nejmoa2025797","article-title":"Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure","volume":"384","author":"Teerlink","year":"2021","journal-title":"New Engl. J. Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of Enalapril on Mortality in Severe Congestive Heart Failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"316","year":"1987","journal-title":"N. Engl. J. Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure","volume":"325","year":"1991","journal-title":"N. Engl. J. Med."},{"volume-title":"User Manual for Trial Sequential Analysis (TSA)","year":"2011","author":"Thorlund","key":"B52"},{"key":"B53","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/jid.2014.37110.1161\/CIRCIMAGING.110.960740","article-title":"Cardiac Involvement in Patients with Muscular Dystrophies: Magnetic Resonance Imaging Phenotype and Genotypic Considerations","volume":"4","author":"Verhaert","year":"2011","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"B54","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.amjcard.2012.02.064","article-title":"Effects of Angiotensin-Converting Enzyme Inhibitors And\/or Beta Blockers on the Cardiomyopathy in Duchenne Muscular Dystrophy","volume":"110","author":"Viollet","year":"2012","journal-title":"Am. J. Cardiol."},{"article-title":"The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomized Studies in Meta-Analyses","year":"2010","author":"Wells","key":"B55"},{"key":"B56","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/1471-2288-9-86","article-title":"Estimating Required Information Size by Quantifying Diversity in Random-Effects Model Meta-Analyses","volume":"9","author":"Wetterslev","year":"2009","journal-title":"BMC Med. Res. Methodol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/j.1440-1681.2006.04394.x","article-title":"Muscle Damage in Mdx (Dystrophic) Mice: Role of Calcium and Reactive Oxygen Species","volume":"33","author":"Whitehead","year":"2006","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.jacc.2017.04.025","article-title":"2017 ACC\/AHA\/HFSA Focused Update of the 2013 ACCF\/AHA Guideline for the\u00a0Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America","volume":"70","author":"Yancy","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s10554-018-1436-8","article-title":"Initial Application of Three-Dimensional Speckle-Tracking Echocardiography to Detect Subclinical Left Ventricular Dysfunction and Stratify Cardiomyopathy Associated with Duchenne Muscular Dystrophy in Children","volume":"35","author":"Yu","year":"2019","journal-title":"Int. J. Cardiovasc. Imaging"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.769896\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T07:45:04Z","timestamp":1642664704000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.769896\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,20]]},"references-count":59,"alternative-id":["10.3389\/fphar.2021.769896"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.769896","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2022,1,20]]},"article-number":"769896"}}